AI assistant
ABBOTT LABORATORIES — Director's Dealing 2025
Feb 28, 2025
29777_dirs_2025-02-27_01128e45-58a9-4dd9-8dfa-35333cfd3b30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2025-02-25
Reporting Person: Salvadori Daniel Gesua Sive (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-25 | Common shares without par value | A | 16534 | — | Acquired | 142231 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-25 | Option (right to buy) | $135.42 | A | 61580 | Acquired | 2035-02-24 | Common Shares (61580) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,526 on February 25, 2026, 20,527 on February 25, 2027, and 20,527 on February 25, 2028.